

Trustee Declarations of Interest

Position	Name	Date Submitted	Personal Interests	Honoraria, Consultations, Grants	Departmental Interests
Past President	Prof Donal O'Donoghue	March 18	Chair of Kidney Care UK	Support from Astra Zeneca to attend the American Society of Nephrology Meeting (November 2017), Support from Vifor Fresenius Medical Care Renal Pharma UK to attend the European Dialysis and Transplant Association Meeting	 Salford Royal Foundation Trust and the Department of Renal Medicine at SRFT have a range of connections and agreements with digital, devices and pharma companies. These are detailed on the SRFT website. Medical Director of Health Innovation Manchester, which also has a range of digital, devices and pharma connections and agreements.
President	Dr Graham Lipkin	Nov 17		 Alexion Pharma-participated in an Advisory Board 2016 Horizon Pharma-Participated as an advisor, in an Advisory Board and spoke at an International RD Conference funded by Horizon 	PI for a study Sponsored by Raptor Pharma and CI for a study with Alnylam, Pharma
Clinical Vice President	Prof Paul Cockwell	April 18		 Janssen – Honoraria for lectures Gilead – Honoraria for contributing to educational resources MSD – Honoraria for lectures KQuiP – Clinical Lead 	The Binding Site
Academic Vice President	Prof Phil Kalra	Nov 17	Medical advisor to Pastest (medical education company)	 Pharmacosmos, Vifor-Fresenius, Astra Zeneca, Janssen: honoraria for lectures and advisory boards during the last 2 years Pharmacosmos, Vifor-Fresenius, Astra Zeneca: support for travel to international meetings (last 2 years): ASN, ERA 	 Shire – educational grant for research (2013-17) Astellas – educational grant for research (2015-17)
Honorary Treasurer	Prof Neil Sheerin	April 18		ERA/EDTA 2018 – Alexion pharmaceuticals – Travel to conference	
Honorary Secretary	Dr Indranil Dasgupta				

Document Updated: December 2018

BAPN President	Dr Sally-Anne Hulton	June 18	 I have received no personal payments or honoraria from any company or group within the last year, all honoraria have been paid into Birmingham Children's Hospital Renal Research Fund Member of Clinical Decision Support Program for Chiesi 24th May 2018 – advisory and consultative duty regarding Cystinosis and its therapy – travel expenses paid Chief Investigator, Alnylam Pharmaceuticals – trial for Primary Hyperoxaluria - Investigators meeting 17th May 2018 - travel and accommodation expenses paid. Honorarium donated to Birmingham Children's Hospital Renal research fund. Chief Investigator, Dicerna Pharmaceutical Company for trial in Primary Hyperoxaluria – attendance at clinical advisory board meeting (Boston 27th April 2018) - travel and accommodation expenses paid. Honorarium paid to Birmingham Children's Hospital Renal research fund. Member of NICE guidance group for management of renal and ureteric stones – on committee until February 2018 when I was advised by NICE to step down in view of a potential conflict of interests as president elect BAPN, one of the stakeholders who 	 Research Involvement Chief Investigator: Anylam Chief Investigator: Dicerna Principle Investigator: OxThera (now completed) Principle Investigator: Laboratory Advicenne (under discussion for potential trial)
----------------	----------------------	---------	---	---